Jean-Samuel Boudreault
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jean-Samuel Boudreault has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Camille Tessier
Université de Sherbrooke Sherbrooke Québec Canada
1 shared publication - Fléchère Fortin
Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, Canada
1 shared publication - Michel Pavic
Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, Canada
1 shared publication - Rayan Kaedbey
Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
1 shared publication - Thomas Allard
Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, Canada
1 shared publication - Vincent Éthier
Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, Canada
1 shared publication
Latest Publications
- Open Access
- 26 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2029-2039
Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone marrow plasma cell (BMPC) percentage > 20%, free light chain ratio (FLCr) > 20 and serum M protein > 20 g/L. The goal of our study was to test this “20/20/20” model in our population and to determine if similar results could be obtained in another cohort of SMM patients. Method—we conducted a retrospective, single center study with 89 patients diagnosed with SMM between January 2008 and December 2019. Results—all three tested biomarkers were associated with an increased risk of progression: BMPC percentage ≥ 20% (hazard ratio [HR]: 4.28 [95%C.I., 1.90–9.61]; p < 0.001), serum M protein ≥ 20 g/L (HR: 4.20 [95%C.I., 1.90–15.53]; p = 0.032) and FLCr ≥ 20 (HR: 3.25 [95%C.I., 1.09–9.71]; p = 0.035). The estimated median time to progression (TTP) was not reached for the low and intermediate risk groups and was 29.1 months (95%C.I., 3.9–54.4) in the high-risk group (p = 0.006). Conclusions—the 20/20/20 risk stratification model adequately predicted progression in our population and is easy to use in various clinical settings.
- 26 May 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2029-2039
Open AccessTesting Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
Background—smoldering multiple myeloma (SMM) risk of progression to multiple myeloma (MM) is highly heterogeneous and several models have been suggested to predict this risk. Lakshman et al. recently proposed a model based on three biomarkers: bone marrow plasma cell (BMPC) percentage > 20%, free light chain ratio (FLCr) > 20 and serum M protein > 20 g/L. The goal of our study was to test this “20/20/20” model in our population and to determine if similar results could be obtained in another cohort of SMM patients. Method—we conducted a retrospective, single center study with 89 patients diagnosed with SMM between January 2008 and December 2019. Results—all three tested biomarkers were associated with an increased risk of progression: BMPC percentage ≥ 20% (hazard ratio [HR]: 4.28 [95%C.I., 1.90–9.61]; p < 0.001), serum M protein ≥ 20 g/L (HR: 4.20 [95%C.I., 1.90–15.53]; p = 0.032) and FLCr ≥ 20 (HR: 3.25 [95%C.I., 1.09–9.71]; p = 0.035). The estimated median time to progression (TTP) was not reached for the low and intermediate risk groups and was 29.1 months (95%C.I., 3.9–54.4) in the high-risk group (p = 0.006). Conclusions—the 20/20/20 risk stratification model adequately predicted progression in our population and is easy to use in various clinical settings.